Skip to main content
Premium Trial:

Request an Annual Quote

Psychiatric Genomics to Close $25M Series B Round Before New Year

WASHINGTON, DC, Oct. 3 – Psychiatric Genomics anticipates closing a Series B round of financing worth between $20 million and $25 million later in the current quarter, the company’s president and CSO told GenomeWeb on Wednesday. 

Michael Palfreyman, who is also Psychiatric Genomics’ founder, could not say what fund will be leading the round, but said that Oxford Bioscience, which led the company’s Series A round, will be a participant.

Psychiatric Genomics, of Gaithersburg, Md., uses its proprietary technology to discover genomic-based therapeutics for a variety of psychiatric disorders, including autism, depression, and schizophrenia, Palfreyman said. He made his remarks privately at the Biotechnology Industry Organization Venture Forum meeting, which is being held here through Thursday.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.